Page last updated: 2024-12-05

oxandrolone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Oxandrolone: A synthetic hormone with anabolic and androgenic properties. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5878
CHEMBL ID1200436
CHEBI ID7820
SCHEMBL ID148881
MeSH IDM0015635

Synonyms (83)

Synonym
AC-14975
AB01559948-01
(4as,4bs,6as,7s,9as,9br,11as)-7-hydroxy-4a,6a,7-trimethyltetradecahydroindeno[4,5-h]isochromen-2(1h)-one
dodecahydro-3-hydroxy-6-(hydroxy-methyl)-3,3a,6-trimethyl-1h-benz(e)indene-7-acetic acid delta-lactone
einecs 200-172-9
2-oxa-5-alpha-androstan-3-one, 17-beta-hydroxy-17-methyl-
hsdb 3373
oxandrolona [inn-spanish]
oxandrin
2-oxaandrostan-3-one, 17-hydroxy-17-methyl-, (5-alpha,17-beta)-
2-oxa-5alpha-androstan-3-one, 17beta-hydroxy-17-methyl-
17-beta-hydroxy-17-methyl-2-oxa-androstan-3-one
8075 cb
oxandrolonum [inn-latin]
sc-11585
2-oxaandrostan-3-one, 17-hydroxy-17-methyl-, (5alpha,17beta)-
nsc 67068
17beta-hydroxy-17-methyl-2-oxa-5alpha-androstan-3-one
ossandrolone [dcit]
lonavar
vasorome
anavar
nsc-67068
8075 c. b.
sc 11585
protivar
provitar
CHEBI:7820 ,
oxandrolonum
oxandrolona
17beta-hydroxy-17alpha-methyl-2-oxa-5alpha-androstan-3-one
C07346
oxandrolone
DB00621
D00462
oxandrin (tn)
oxandrolone (jan/usp/inn)
CHEMBL1200436
oxandrolone ciii
(1s,3as,3br,5as,9as,9bs,11as)-1-hydroxy-1,9a,11a-trimethyl-2,3,3a,3b,4,5,5a,6,9,9b,10,11-dodecahydroindeno[4,5-h]isochromen-7-one
17alpha-methyl-17beta-hydroxy-2-oxa-5alpha-androstan-3-one
7h6tm3ct4l ,
8075 c.b.
oxandrolone [usan:usp:inn:ban:jan]
unii-7h6tm3ct4l
ossandrolone
oxandrolone [mi]
oxandrolone [jan]
oxandrolone [mart.]
oxandrolone ciii [usp-rs]
oxandrolone [orange book]
oxandrolone [who-dd]
oxandrolone [hsdb]
oxandrolone [vandf]
oxandrolone [inn]
oxandrolone [usan]
oxandrolone [usp monograph]
gtpl7092
CCG-220110
HY-B0707
SCHEMBL148881
QSLJIVKCVHQPLV-PEMPUTJUSA-N
W-105740
DTXSID8023399 ,
AKOS025401400
(1s,2s,7s,10r,11s,14s,15s)-14-hydroxy-2,14,15-trimethyl-4-oxatetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecan-5-one
SR-01000872645-1
sr-01000872645
oxandrolone, >=98% (hplc)
HMS3712E22
Q420859
oxandrin;anavar
bdbm50594919
oxandrolone (usan:usp:inn:ban:jan)
oxandrolona (inn-spanish)
oxandrolon
a14aa08
dtxcid203399
oxandrolone (mart.)
oxandrolone (usp monograph)
oxandrolone ciii (usp-rs)
oxandrolonum (inn-latin)
dodecahydro-3-hydroxy-6-(hydroxy-methyl)-3,3a,6-trimeth yl-1h-benz

Research Excerpts

Overview

Oxandrolone (OXA) is an androgen and anabolic steroid (AAS) that is used to reverse weight loss associated with some medical conditions. It is a potent synthetic testosterone analogue that possesses strong anabolic property and weak androgenic activity.

ExcerptReferenceRelevance
"Oxandrolone is a synthetic testosterone analog that is widely used among bodybuilders and athletes. "( The Protective Effect of Metformin against Oxandrolone-Induced Infertility in Male Rats.
Abed, AF; Al-Ameer, HJ; Al-Awaida, W; Jarrar, YB; Lee, SJ, 2022
)
2.43
"Oxandrolone (OXA) is a synthetic steroid used for the treatment of clinical conditions associated with catabolic states in humans, including children. "( Oxandrolone treatment in juvenile rats induced anxiety-like behavior in young adult animals.
Bernardina, NRD; Bissoli, NS; Brasil, GA; de Lima, RMS; Rodrigues, LC; Ronchi, SN; Souza, GJ; Wan Der Mass, EM, 2021
)
3.51
"Oxandrolone (OXA) is an androgen and anabolic steroid (AAS) that is used to reverse weight loss associated with some medical conditions. "( Metformin reduces oxandrolone- induced depression-like behavior in rats via modulating the expression of IL-1β, IL-6, IL-10 and TNF-α.
Abed, AF; Alfaraj, M; Hall, FS; Hammad, AM; Ibrahim, YA; Jarrar, Y; Khdair, SI, 2021
)
2.4
"Oxandrolone is an anabolic-androgenic steroid with favourable anabolic to androgenic ratio, making it an effective anabolic agent with less androgenic side effects. "( In vitro and in vivo metabolism of the anabolic-androgenic steroid oxandrolone in the horse.
Biddle, S; Cutler, C; Habershon-Butcher, J; Harding, C; Scarth, J; Viljanto, M, 2022
)
2.4
"Oxandrolone is a synthetic oral non-aromatizable testosterone derivative. "( Oxandrolone protects against the development of multiorgan failure, modulates the systemic inflammatory response and promotes wound healing during burn injury.
Ahmad, A; Herndon, DN; Szabo, C, 2019
)
3.4
"Oxandrolone is an anabolic steroid used to promote weight gain for cachectic patients with severe burn injuries, HIV/AIDS, hepatitis C and other wasting syndromes."( Quantitative Assay Validation for Oxandrolone in Human Plasma Using LC-MS-MS.
Burch, PT; Campbell, SC; Lambert, LM; Linakis, MW; Reilly, CA; Sherwin, CM; Spigarelli, MG; Stockmann, C; Williams, RV, 2015
)
1.42
"Oxandrolone is a potent synthetic testosterone analogue that possesses strong anabolic property and weak androgenic activity. "( Transdermal Oxandrolone: Ex Vivo Percutaneous Absorption Study.
Brandão, MAF; de Oliveira Ferreira, A; Polonini, H; Raposo, NRB, 2017
)
2.28
"Oxandrolone appears to be a promising anabolic agent although few outcome data are as yet available."( Impact of oxandrolone treatment on acute outcomes after severe burn injury.
Arnoldo, BD; Finnerty, CC; Gamelli, RL; Gibran, NS; Herndon, DN; Jeschke, MG; Klein, MB; Pham, TN; Silver, GM; Tompkins, RG,
)
1.26
"Oxandrolone is an androgenic steroid with potential neuroprotective properties that is used to prevent muscle loss and is not immunosuppressive."( Improved functional recovery with oxandrolone after spinal cord injury in rats.
Bauman, WA; Cardozo, CP; Etlinger, JD; Ouyang, N; Wen, X; Zeman, RJ, 2009
)
1.35
"Oxandrolone is an effective adjunct to facilitate weight restoration in patients with COPD-associated weight loss. "( Reversal of COPD-associated weight loss using the anabolic agent oxandrolone.
DeGuzman, B; Kramer, T; Yeh, SS, 2002
)
2
"Oxandrolone is a synthetic anabolic steroid with limited virilizing effects that has been used in a variety of pediatric conditions and has an acceptable safety profile."( Oxandrolone treatment of childhood hereditary angioedema.
Church, JA, 2004
)
2.49
"Oxandrolone is an anabolic steroid that attenuates loss of lean body mass and improves wound healing in burn patients."( Oxandrolone does not improve outcome of ventilator dependent surgical patients.
Bulger, EM; Farver, CL; Jurkovich, GJ; Klotz, P; Maier, RV, 2004
)
2.49
"Oxandrolone is an anabolic agent shown to decrease lean mass catabolism and improve wound healing in the severely burned patients."( Effects of oxandrolone on outcome measures in the severely burned: a multicenter prospective randomized double-blind trial.
Baker, R; Benjamin, W; Burris, A; Cairns, B; Caruso, D; Crean, D; Cross, J; Donison, L; Edelman, LS; Edwards, P; Foster, K; Greenhalgh, DG; Hatfield, S; Hildebrand, B; Hunt, J; Jeng, J; Kagan, R; Kemalyan, N; Kessler, M; Klein, RL; Lawless, M; Noppenberger, D; Palmieri, TL; Purdue, G; Saffle, J; Sanford, AP; Spence, RJ; Tutulo, W; Underwood, M; Villarreal, C; Voigt, D; Warner, P; Wolf, SE; Yowler, C,
)
1.24
"Oxandrolone is an anabolic steroid that has been used in cachectic hepatitis and AIDS patients."( Anabolic effects of oxandrolone after severe burn.
Beauford, RB; Chinkes, DL; Ferrando, AA; Hart, DW; Herndon, DN; Ramzy, PI; Wolf, SE; Wolfe, RR, 2001
)
1.36
"Oxandrolone is a Schedule III controlled substance."( Wasting syndrome: oral oxandrolone re-released in U.S.
James, JS, 1995
)
1.32
"Oxandrolone is a 5 alpha-reduced anabolic steroid that is administered for the treatment of short stature disease in children. "( The effects of an anabolic steroid (oxandrolone) on reproductive development in the male rat.
Ahmad, N; Grokett, BH; Warren, DW, 1992
)
2
"Oxandrolone is a safe and effective treatment for prepubertal boys with constitutional growth delay."( Treatment of constitutional growth delay in prepubertal boys with a prolonged course of low dose oxandrolone.
Papadimitriou, A; Pearl, K; Preece, MA; Stanhope, R; Wacharasindhu, S, 1991
)
1.22

Effects

Oxandrolone has proven benefits in thermal burn injury and has become a standard of care. It has an androgenic action as shown by changes in serum LH, testosterone and SHBG concentrations.

ExcerptReferenceRelevance
"Oxandrolone has an androgenic action as shown by changes in serum LH, testosterone and SHBG concentrations and by the lack of effect on FSH. "( The effects of oxandrolone on the growth hormone and gonadal axes in boys with constitutional delay of growth and puberty.
Brook, CG; Hindmarsh, PC; Malhotra, A; Poon, E; Pringle, PJ; Tse, WY, 1993
)
2.08
"Oxandrolone has proven benefits in thermal burn injury and has become a standard of care. "( Risk Factors Associated with the Development of Transaminitis in Oxandrolone-Treated Adult Burn Patients.
Foster, CJ; Gayed, RM; Hill, DM; Jones, KM; Kiracofe, B; Murphy, CV; Oltrogge Pape, K; Porter, K; Reger, M; Zavala, S, 2019
)
2.19
"Oxandrolone has been shown to improve lean muscle mass in patients with burns. "( Incidence of hepatic dysfunction is equivalent in burn patients receiving oxandrolone and controls.
Goldberg, S; Gomez, E; Manning, R; McCullough, MC; Namias, N; Pizano, L; Schulman, C; Ward, GC,
)
1.8
"Oxandrolone has an androgenic action as shown by changes in serum LH, testosterone and SHBG concentrations and by the lack of effect on FSH. "( The effects of oxandrolone on the growth hormone and gonadal axes in boys with constitutional delay of growth and puberty.
Brook, CG; Hindmarsh, PC; Malhotra, A; Poon, E; Pringle, PJ; Tse, WY, 1993
)
2.08

Actions

ExcerptReferenceRelevance
"Oxandrolone may enhance collagen deposition and fibrosis in the later stages of acute respiratory distress syndrome and thus prolong recovery."( Oxandrolone does not improve outcome of ventilator dependent surgical patients.
Bulger, EM; Farver, CL; Jurkovich, GJ; Klotz, P; Maier, RV, 2004
)
2.49

Treatment

Oxandrolone treatment (1mg/kg/day for up to 21 days) significantly ameliorated burn-induced accumulation of myeloperoxidase levels in heart and lung (but not the liver and kidney) The treatment augmented increases in lean tissue for the whole body (2.6 kg)

ExcerptReferenceRelevance
"In oxandrolone-treated mice (1mg/kg/day for up to 21 days) there was a significant amelioration of burn-induced accumulation of myeloperoxidase levels in heart and lung (but not the liver and kidney) and significantly lower degree of malon dialdehyde accumulation in the liver (but not the heart, lung and kidney)."( Oxandrolone protects against the development of multiorgan failure, modulates the systemic inflammatory response and promotes wound healing during burn injury.
Ahmad, A; Herndon, DN; Szabo, C, 2019
)
2.47
"Oxandrolone treatment augmented increases in lean tissue for the whole body (2.6 kg; 95% confidence interval (CI), 1.0-4.2 kg; P = 0.003), arms (0.3 kg; 95% CI, 0.1-0.5 kg; P = 0.001), legs (0.8 kg; 95% CI, 0.1-1.4 kg; P = 0.018), and trunk (1.4 kg; 95% CI, 0.4-2.3 kg; P = 0.004). "( Oxandrolone Augmentation of Resistance Training in Older Women: A Randomized Trial.
Bean, JF; Broe, K; Connerty, M; Fielding, RA; Kiel, DP; Maclean, D; Mavros, Y; O'Neill, E; Singh, MA; Taylor, A, 2015
)
3.3
"Oxandrolone treatment (N = 59) did not impact length of stay but was associated with a lower mortality rate (P = .01) by univariate analysis."( Impact of oxandrolone treatment on acute outcomes after severe burn injury.
Arnoldo, BD; Finnerty, CC; Gamelli, RL; Gibran, NS; Herndon, DN; Jeschke, MG; Klein, MB; Pham, TN; Silver, GM; Tompkins, RG,
)
1.26
"Oxandrolone-treated children exhibited improved height percentile and BMC content compared with controls."( Five-year outcomes after oxandrolone administration in severely burned children: a randomized clinical trial of safety and efficacy.
Finnerty, CC; Herndon, DN; Jennings, K; Klein, GL; Lee, JO; Meyer, WJ; Mlcak, RP; Porro, LJ; Rodriguez, NA; Suman, OE, 2012
)
1.4
"The oxandrolone-treated group demonstrated improved performance after 2 yr, compared with the placebo group (P < 0.03)."( Androgen-responsive aspects of cognition in girls with Turner syndrome.
Bondy, C; Cutler, GB; Feuillan, P; Kushner, H; Roeltgen, D; Ross, JL; Stefanatos, GA, 2003
)
0.8
"Oxandrolone treatment was associated with significant clinical and laboratory evidence of a therapeutic effect in a prepuberal boy with HAE. "( Oxandrolone treatment of childhood hereditary angioedema.
Church, JA, 2004
)
3.21
"Oxandrolone treatment showed a positive effect on bone mass during the first few years of therapy."( [Study of bone mass in Turner syndrome].
Cancer Gaspar, E; Ferrández Longás, A; Labarta Aizpún, JI; Mayayo Dehesa, E; Ruiz-Echarri Zelaya, M, 2005
)
1.05
"Oxandrolone treatment was associated with significant suppression of sex hormone-binding globulin, luteinizing hormone, follicle-stimulating hormone, and total and free testosterone levels."( Oxandrolone in the treatment of HIV-associated weight loss in men: a randomized, double-blind, placebo-controlled study.
Bhasin, S; Dobs, A; Glesby, M; Grunfeld, C; Kotler, DP, 2006
)
2.5
"The oxandrolone-treated boys were divided into two groups: four boys who received oxandrolone before onset of puberty (group 2), and 14 boys who started oxandrolone therapy during Tanner stage 2 (group 3)."( The effect of prolonged administration of an anabolic steroid (oxandrolone) on growth in boys with constitutionally delayed growth and puberty.
Delemarre-van de Waal, HA; Knibbe, P; Schroor, EJ; van Weissenbruch, MM, 1995
)
1.01
"Oxandrolone may also be a treatment option, due to reports which suggest that long term use can result in increased body mass."( Body composition changes with protease therapy.
Berger, D,
)
0.85
"Treatment with oxandrolone was associated with modest improvements in PFTs and in arm and total body LBM."( The effects of an anabolic agent on body composition and pulmonary function in tetraplegia: a pilot study.
Groah, SL; Halstead, LS; Hamm, LF; Libin, A; Priestley, L, 2010
)
0.7
"Treatment with oxandrolone in severe burns significantly increases constitutive protein and reduces acute phase protein levels."( The long-term effect of oxandrolone on hepatic acute phase proteins in severely burned children.
Chinkes, DL; Herndon, DN; Murphy, KD; Thomas, S; Wolf, SE, 2004
)
0.98
"Treatment with oxandrolone for 3 months in HIV-infected children was well-tolerated, safe, and associated with markers of anabolism. "( Evaluation of the effects of oxandrolone on malnourished HIV-positive pediatric patients.
Barton, N; Church, JA; Fox-Wheeler, S; Gilsanz, V; Haight, M; Heller, L; Kaufman, F; Loro, ML; Salata, CM; Umman, GC, 1999
)
0.95

Toxicity

Oxandrolone is reported to be generally well tolerated. The most commonly documented adverse effects are transient elevations in transaminase levels and reductions in high density lipoprotein cholesterol level.

ExcerptReferenceRelevance
" No adverse reactions attributable to oxandrolone were recorded."( A randomized efficacy and safety trial of oxandrolone in the treatment of Duchenne dystrophy.
Fenichel, GM; Florence, J; Griggs, RC; King, WM; Kissel, J; Kramer, TI; Mendell, JR; Moxley, RT; Pandya, S; Pestronk, A; Robison, VD; Sheng, K; Wang, H, 2001
)
0.85
" Oxandrolone is reported to be generally well tolerated and the most commonly documented adverse effects are transient elevations in transaminase levels and reductions in high density lipoprotein cholesterol level."( The anabolic androgenic steroid oxandrolone in the treatment of wasting and catabolic disorders: review of efficacy and safety.
Fiatarone Singh, M; Orr, R, 2004
)
1.52

Compound-Compound Interactions

The aims of this comparative multicenter study of 67 girls with Turner syndrome (TS) were to evaluate the effect of either recombinant human growth hormone (GH) alone or in combination with the anabolic steroid oxandrolone (Oxa) and to estimate the gain in final height.

ExcerptReferenceRelevance
" Conventional GH doses are effective in increasing growth velocity in UTS, especially, when combined with Ox."( Treatment of patients with Ullrich-Turner syndrome with conventional doses of growth hormone and the combination with testosterone or oxandrolone: effect on growth, IGF-I and IGFBP-3 concentrations.
Blümel, P; Frisch, H; Haeusler, G; Plöchl, E; Schmitt, K; Waldhör, T; Zachmann, M, 1995
)
0.49
"We have studied the course over age of fasting insulin, sex hormone-binding globulin (SHBG), and insulin-like growth factor (IGF)-binding protein-1 (IGFBP-1) in untreated children with Turner's syndrome (TS) and measured the course of these parameters during therapy with GH alone and in combination with oxandrolone."( Insulin, insulin-like growth factor-binding protein-1, and sex hormone-binding globulin in patients with Turner's syndrome: course over age in untreated patients and effect of therapy with growth hormone alone and in combination with oxandrolone.
Blümel, P; Frisch, H; Haeusler, G; Plöchl, E; Schmitt, K; Waldhör, T, 1996
)
0.65
" Subsequently, all patients received GH 18 IU/m2/week in combination with oxandrolone (Ox) (0."( Growth hormone in combination with anabolic steroids in patients with Turner syndrome: effect on bone maturation and final height.
Blümel, P; Frisch, H; Haeusler, G; Plöchl, E; Schmitt, K; Waldhör, T, 1996
)
0.52
"The aims of this comparative multicenter study of 67 girls with Turner syndrome (TS) on three different therapeutical regimens were, first, to evaluate the effect of either recombinant human growth hormone (GH) alone or in combination with the anabolic steroid oxandrolone (Oxa) on height velocity and on Turner-specific bone age (BA'TS) and, second, to estimate the gain in final height taking the age at the onset of treatment into account."( Growth promotion and Turner-specific bone age after therapy with growth hormone and in combination with oxandrolone: when should therapy be started in Turner syndrome?
Joss, EE; Mullis, PE; Partsch, CJ; Sippell, WG; Werder, EA, 1997
)
0.69

Bioavailability

ExcerptReferenceRelevance
" The decline in weight-for-age z-score was lowest in those receiving the MCT oil preparation suggesting better bioavailability of this preparation and a potential growth benefit with oxandrolone therapy."( Use of Oxandrolone to Promote Growth in Neonates following Surgery for Complex Congenital Heart Disease: An Open-Label Pilot Trial.
Burch, PT; Lambert, LM; Linakis, MW; Loftus, PD; LuAnn Minich, L; Sheng, X; Sherwin, CM; Spigarelli, MG; Williams, RV, 2016
)
1.08

Dosage Studied

Oxandrolone is a synthetic non-fluorinated anabolic steroid, similar to oxymetholone. The study found no significant effect on the pattern of pubertal growth. Multicenter, prospective, randomized studies are needed to better define the optimal dosage.

ExcerptRelevanceReference
" Oestrogens are needed for secondary sex characteristics, but should be given in a low dosage and at approximately 12-13 years of age, in order not to compromise final height."( [Turner syndrome: a virtually certain indication for growth hormone treatment].
Rongen-Westerlaken, C; Wit, JM, 1992
)
0.28
" There is a dose-response relationship."( [Growth hormone treatment in short stature of unknown origin].
Wit, JM, 1992
)
0.28
" Half of the compounds decreased uterine weight at lower doses but increased it at higher doses within the dosage range (1-4000 micrograms/day)."( Anti-ovulatory effects of some androgenic-myotrophic steroids in the pubertal rat.
Boris, A; Nelson, EW; Trmal, T, 1972
)
0.25
" IGFBP-3 concentrations were in the upper normal range before therapy and increased only moderately in both GH dosage groups."( Treatment of patients with Ullrich-Turner syndrome with conventional doses of growth hormone and the combination with testosterone or oxandrolone: effect on growth, IGF-I and IGFBP-3 concentrations.
Blümel, P; Frisch, H; Haeusler, G; Plöchl, E; Schmitt, K; Waldhör, T; Zachmann, M, 1995
)
0.49
" However, a more lengthy study is needed in order to assess the efficacy of treatment with regard to adult height prognosis and to determine the optimal dosing required."( Oxandrolone therapy in skeletal dysplasia.
Büyükgebiz, A; Kovanlikaya, I,
)
1.57
" Our data suggest that 6 months-1 year, low dosage oxandrolone treatment in constitutionally delayed growth has no significant effect on the pattern of pubertal growth, nor on the rate of sexual maturation or on final height."( Oxandrolone in constitutional delay of growth: analysis of the growth patterns up to final stature.
Bassi, F; Cheli, D; Gheri, RG; Neri, AS; Serio, M, 1993
)
1.98
" Oxandrolone was given in the beginning of the recovery phase in a dosage of 10 mg orally twice a day."( Oxandrolone, an anabolic steroid, significantly increases the rate of weight gain in the recovery phase after major burns.
Demling, RH; DeSanti, L, 1997
)
2.65
" The two groups were similar for demographics and dosage of enteral nutrition."( Oxandrolone in trauma patients.
Brown, RO; Croce, MA; Dickerson, RN; Fabian, TC; Gervasio, JM; Swearingen, J; Yates, ME; Yuen, C, 2000
)
1.75
" Several small studies have shown encouraging results for HIV-related weight loss when doses two to eight times the recommended dosage were used."( Oxandrolone for weight gain.
, 1997
)
1.74
" Multicenter, prospective, randomized studies are needed to better define the optimal oxandrolone dosage and to confirm the efficacy and safety of this drug in adult patients with severe thermal injury."( Oxandrolone treatment in adults with severe thermal injury.
Btaiche, IF; Miller, JT, 2009
)
2.02
" The changes during Ox/Pl therapy were not significantly different between the dosage groups."( The effect of the weak androgen oxandrolone on psychological and behavioral characteristics in growth hormone-treated girls with Turner syndrome.
Cohen-Kettenis, PT; de Muinck Keizer-Schrama, SM; Kreukels, BP; Menke, LA; Otten, BJ; Sas, TC; Stijnen, T; Visser, M; Wit, JM; Zandwijken, GR, 2010
)
0.64
"A randomized, placebo-controlled, double-blind, dose-response study was performed in 10 centers in The Netherlands."( Efficacy and safety of oxandrolone in growth hormone-treated girls with turner syndrome.
de Muinck Keizer-Schrama, SM; de Ridder, MA; Dejonckere, PH; Delemarre-van de Waal, HA; Gevers, EF; Hokken-Koelega, AC; Jansen, M; Menke, LA; Odink, RJ; Otten, BJ; Reeser, HM; Sas, TC; Stokvis-Brantsma, WH; van Buuren, S; van Trotsenburg, AS; Waelkens, JJ; Westerlaken, C; Wit, JM; Zandwijken, GR, 2010
)
0.67
"In GH-treated girls with TS, we discourage the use of the conventional Ox dosage (0."( Efficacy and safety of oxandrolone in growth hormone-treated girls with turner syndrome.
de Muinck Keizer-Schrama, SM; de Ridder, MA; Dejonckere, PH; Delemarre-van de Waal, HA; Gevers, EF; Hokken-Koelega, AC; Jansen, M; Menke, LA; Odink, RJ; Otten, BJ; Reeser, HM; Sas, TC; Stokvis-Brantsma, WH; van Buuren, S; van Trotsenburg, AS; Waelkens, JJ; Westerlaken, C; Wit, JM; Zandwijken, GR, 2010
)
0.67
" The increase in BMI and waist circumference SDS was comparable between the dosage groups."( The effect of oxandrolone on body proportions and body composition in growth hormone-treated girls with Turner syndrome.
de Muinck Keizer-Schrama, SM; de Ridder, MA; Menke, LA; Otten, BJ; Sas, TC; Stijnen, T; Wit, JM; Zandwijken, GR, 2010
)
0.72
"003) without significant differences between the dosage groups."( Effect of oxandrolone on glucose metabolism in growth hormone-treated girls with Turner syndrome.
de Muinck Keizer-Schrama, SM; Menke, LA; Otten, BJ; Sas, TC; Stijnen, T; Wit, JM; Zandwijken, GR, 2011
)
0.77
" The percentage of patients reporting subjective voice deepening was similar between the dosage groups."( The effect of oxandrolone on voice frequency in growth hormone-treated girls with Turner syndrome.
Boersma, B; de Muinck Keizer-Schrama, SM; de Ridder, MA; Dejonckere, PH; Menke, LA; Otten, BJ; Sas, TC; van Koningsbrugge, SH; Wit, JM; Zandwijken, GR, 2011
)
0.73
" We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts."( FDA-approved drug labeling for the study of drug-induced liver injury.
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011
)
0.37
" However, there is an absence of dosage form alternatives as it is only available as tablets."( Development of an extemporaneous oral liquid formulation of oxandrolone and its stability evaluation.
Garg, A; Garg, S; She, RW, 2011
)
0.61
" In this study we aimed to evaluate the toxicity profile and hematologic response in patients with FA who are treated with low-dose oxandrolone, a synthetic non-fluorinated anabolic steroid, similar to oxymetholone, with known dosing thresholds for virilization."( Oxandrolone for the treatment of bone marrow failure in Fanconi anemia.
Bollepalli, S; Eyal, O; Harris, R; Jeng, MR; Kim, MO; Korbee, L; Ris, MD; Rose, SR; Sherafat-Kazemzadeh, R; Smith, FO; Williams, DA; Wilson, KA, 2014
)
2.05
" Further investigation is needed to define optimal dosing and assess efficacy."( Use of Oxandrolone to Promote Growth in Neonates following Surgery for Complex Congenital Heart Disease: An Open-Label Pilot Trial.
Burch, PT; Lambert, LM; Linakis, MW; Loftus, PD; LuAnn Minich, L; Sheng, X; Sherwin, CM; Spigarelli, MG; Williams, RV, 2016
)
0.89
" Plasma propranolol concentrations were determined following two dosing strategies: Q6 (liquid formulation; n = 86) and Q24 (extended-release capsule; n = 22)."( Oxandrolone Coadministration Does Not Alter Plasma Propranolol Concentrations in Severely Burned Pediatric Patients.
Andersen, CR; Finnerty, CC; Guillory, AN; Herndon, DN; Silva, MB; Suman, OE,
)
1.57
" The main source of information on AASs, doses, and dosage patterns was the Internet (48."( [The medical aspect of using anabolic androgenic steroids in males attending gyms of Saint-Petersburg].
Babenko, AY; Lykhonosov, MP, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
androgenA sex hormone that stimulates or controls the development and maintenance of masculine characteristics in vertebrates by binding to androgen receptors.
anabolic agentA compound which stimulates anabolism and inhibits catabolism. Anabolic agents stimulate the development of muscle mass, strength, and power.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
3-oxo steroidAny oxo steroid where an oxo substituent is located at position 3.
oxa-steroidA steroid where in the carbon skeleton a carbon atom is replaced by oxygen.
17beta-hydroxy steroidA 17-hydroxy steroid in which the hydroxy group at position 17 has a beta-configuration.
anabolic androgenic steroidA steroid hormone related to the hormone testosterone. It increases protein synthesis within cells, which results in the buildup of cellular tissue (anabolism), especially in muscles. It also has androgenic and virilizing properties.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Androgen receptorHomo sapiens (human)IC50 (µMol)0.00080.00000.875310.0000AID1872312
Androgen receptorHomo sapiens (human)Ki0.06200.00020.42407.2000AID1885021
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (56)

Processvia Protein(s)Taxonomy
negative regulation of transcription by RNA polymerase IIAndrogen receptorHomo sapiens (human)
MAPK cascadeAndrogen receptorHomo sapiens (human)
in utero embryonic developmentAndrogen receptorHomo sapiens (human)
regulation of systemic arterial blood pressureAndrogen receptorHomo sapiens (human)
epithelial cell morphogenesisAndrogen receptorHomo sapiens (human)
transcription by RNA polymerase IIAndrogen receptorHomo sapiens (human)
signal transductionAndrogen receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAndrogen receptorHomo sapiens (human)
cell-cell signalingAndrogen receptorHomo sapiens (human)
spermatogenesisAndrogen receptorHomo sapiens (human)
single fertilizationAndrogen receptorHomo sapiens (human)
positive regulation of cell population proliferationAndrogen receptorHomo sapiens (human)
negative regulation of cell population proliferationAndrogen receptorHomo sapiens (human)
positive regulation of gene expressionAndrogen receptorHomo sapiens (human)
male somatic sex determinationAndrogen receptorHomo sapiens (human)
intracellular estrogen receptor signaling pathwayAndrogen receptorHomo sapiens (human)
androgen receptor signaling pathwayAndrogen receptorHomo sapiens (human)
intracellular receptor signaling pathwayAndrogen receptorHomo sapiens (human)
positive regulation of intracellular estrogen receptor signaling pathwayAndrogen receptorHomo sapiens (human)
Leydig cell differentiationAndrogen receptorHomo sapiens (human)
multicellular organism growthAndrogen receptorHomo sapiens (human)
positive regulation of phosphorylationAndrogen receptorHomo sapiens (human)
positive regulation of MAPK cascadeAndrogen receptorHomo sapiens (human)
positive regulation of insulin-like growth factor receptor signaling pathwayAndrogen receptorHomo sapiens (human)
positive regulation of cell differentiationAndrogen receptorHomo sapiens (human)
negative regulation of integrin biosynthetic processAndrogen receptorHomo sapiens (human)
positive regulation of integrin biosynthetic processAndrogen receptorHomo sapiens (human)
positive regulation of DNA-templated transcriptionAndrogen receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIAndrogen receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIIAndrogen receptorHomo sapiens (human)
insulin-like growth factor receptor signaling pathwayAndrogen receptorHomo sapiens (human)
regulation of developmental growthAndrogen receptorHomo sapiens (human)
animal organ formationAndrogen receptorHomo sapiens (human)
male genitalia morphogenesisAndrogen receptorHomo sapiens (human)
epithelial cell proliferationAndrogen receptorHomo sapiens (human)
negative regulation of epithelial cell proliferationAndrogen receptorHomo sapiens (human)
positive regulation of NF-kappaB transcription factor activityAndrogen receptorHomo sapiens (human)
activation of prostate induction by androgen receptor signaling pathwayAndrogen receptorHomo sapiens (human)
morphogenesis of an epithelial foldAndrogen receptorHomo sapiens (human)
lateral sprouting involved in mammary gland duct morphogenesisAndrogen receptorHomo sapiens (human)
prostate gland growthAndrogen receptorHomo sapiens (human)
prostate gland epithelium morphogenesisAndrogen receptorHomo sapiens (human)
epithelial cell differentiation involved in prostate gland developmentAndrogen receptorHomo sapiens (human)
tertiary branching involved in mammary gland duct morphogenesisAndrogen receptorHomo sapiens (human)
mammary gland alveolus developmentAndrogen receptorHomo sapiens (human)
positive regulation of epithelial cell proliferation involved in prostate gland developmentAndrogen receptorHomo sapiens (human)
cellular response to steroid hormone stimulusAndrogen receptorHomo sapiens (human)
cellular response to estrogen stimulusAndrogen receptorHomo sapiens (human)
cellular response to testosterone stimulusAndrogen receptorHomo sapiens (human)
seminiferous tubule developmentAndrogen receptorHomo sapiens (human)
non-membrane-bounded organelle assemblyAndrogen receptorHomo sapiens (human)
positive regulation of miRNA transcriptionAndrogen receptorHomo sapiens (human)
regulation of protein localization to plasma membraneAndrogen receptorHomo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathwayAndrogen receptorHomo sapiens (human)
male gonad developmentAndrogen receptorHomo sapiens (human)
intracellular steroid hormone receptor signaling pathwayAndrogen receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (23)

Processvia Protein(s)Taxonomy
transcription cis-regulatory region bindingAndrogen receptorHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingAndrogen receptorHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificAndrogen receptorHomo sapiens (human)
RNA polymerase II general transcription initiation factor bindingAndrogen receptorHomo sapiens (human)
transcription coactivator bindingAndrogen receptorHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificAndrogen receptorHomo sapiens (human)
chromatin bindingAndrogen receptorHomo sapiens (human)
DNA-binding transcription factor activityAndrogen receptorHomo sapiens (human)
nuclear receptor activityAndrogen receptorHomo sapiens (human)
G protein-coupled receptor activityAndrogen receptorHomo sapiens (human)
signaling receptor bindingAndrogen receptorHomo sapiens (human)
steroid bindingAndrogen receptorHomo sapiens (human)
androgen bindingAndrogen receptorHomo sapiens (human)
protein bindingAndrogen receptorHomo sapiens (human)
beta-catenin bindingAndrogen receptorHomo sapiens (human)
zinc ion bindingAndrogen receptorHomo sapiens (human)
enzyme bindingAndrogen receptorHomo sapiens (human)
ATPase bindingAndrogen receptorHomo sapiens (human)
molecular adaptor activityAndrogen receptorHomo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingAndrogen receptorHomo sapiens (human)
POU domain bindingAndrogen receptorHomo sapiens (human)
molecular condensate scaffold activityAndrogen receptorHomo sapiens (human)
estrogen response element bindingAndrogen receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (8)

Processvia Protein(s)Taxonomy
plasma membraneAndrogen receptorHomo sapiens (human)
nucleusAndrogen receptorHomo sapiens (human)
nucleoplasmAndrogen receptorHomo sapiens (human)
cytoplasmAndrogen receptorHomo sapiens (human)
cytosolAndrogen receptorHomo sapiens (human)
nuclear speckAndrogen receptorHomo sapiens (human)
chromatinAndrogen receptorHomo sapiens (human)
protein-containing complexAndrogen receptorHomo sapiens (human)
nucleusAndrogen receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (43)

Assay IDTitleYearJournalArticle
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID625276FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of most concern for DILI2011Drug discovery today, Aug, Volume: 16, Issue:15-16
FDA-approved drug labeling for the study of drug-induced liver injury.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1872312Inhibition of Androgen receptor (unknown origin)2022European journal of medicinal chemistry, Feb-15, Volume: 230Overview of the development of selective androgen receptor modulators (SARMs) as pharmacological treatment for osteoporosis (1998-2021).
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1885021Binding affinity to human Androgen receptor2022Journal of medicinal chemistry, 07-14, Volume: 65, Issue:13
Therapeutic Strategies to Target the Androgen Receptor.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (453)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990155 (34.22)18.7374
1990's98 (21.63)18.2507
2000's95 (20.97)29.6817
2010's81 (17.88)24.3611
2020's24 (5.30)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 98.07

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index98.07 (24.57)
Research Supply Index6.44 (2.92)
Research Growth Index4.47 (4.65)
Search Engine Demand Index181.47 (26.88)
Search Engine Supply Index2.03 (0.95)

This Compound (98.07)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials131 (26.52%)5.53%
Reviews68 (13.77%)6.00%
Case Studies35 (7.09%)4.05%
Observational0 (0.00%)0.25%
Other260 (52.63%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (19)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Randomized Controlled Pilot Study of Goal-directed Iron Supplementation of Anemic, Critically Ill Trauma Patients With Functional Iron Deficiency, With and Without Oxandrolone [NCT02047552]Phase 20 participants (Actual)Interventional2015-01-31Withdrawn(stopped due to No Participants enrolled)
Ability of Oral Oxandrolone to Aid in Rehabilitation and Outcomes of Multiligament Knee Reconstructions: A Double-Blind, Randomized Controlled Trial [NCT05893069]Phase 460 participants (Anticipated)Interventional2023-07-01Recruiting
Compare the Relative Bioavailability of Oxandrolone 10mg Tablets With That of OXANDRIN 10 mg Tablets Following a Single Oral Dose(1*10 mg Tablet) in Healthy, Adult Subjects Under Fasting Conditions. [NCT00652886]Phase 126 participants (Actual)Interventional2005-03-31Completed
A Pilot Study of the Safety and Efficacy of Oxandrolone in the Prevention and Treatment of Malnutrition in Infants After Cardiac Surgery [NCT01048632]Phase 120 participants (Actual)Interventional2010-07-31Completed
Use of Oxandrolone to Promote Growth in Infants With Hypoplastic Left Heart Syndrome: A Phase I/II Pilot Study [NCT04090697]Phase 1/Phase 2100 participants (Anticipated)Interventional2019-12-20Suspended(stopped due to FDA withdrawal of Oxandrin NDA and generic ANDAs)
A Pilot Trial of Oxandrolone for the Treatment of Bone Marrow Aplasia in Patients With Fanconi Anemia [NCT00243399]Phase 110 participants (Anticipated)Interventional2004-07-31Completed
The Use of Oxandrolone to Improve Function in Persons With Chronic Spinal Cord Injury [NCT00223769]40 participants Interventional2004-01-31Completed
Assessment of Mechanisms of Improved Wound Healing of Anabolic Agents and Diet in Severely Burned Patients [NCT00673309]Phase 2/Phase 3644 participants (Actual)Interventional2000-07-31Completed
Assessment of the Treatment of the Severely Burned With Anabolic Agents on Clinical Outcomes, Recovery and Rehabilitation [NCT00675714]Phase 2/Phase 31,126 participants (Actual)Interventional2004-01-31Terminated(stopped due to At the request of the study site, this study has been closed and access to study-related data is unavailable. We are unable to submit the results-data.)
[NCT00006167]Phase 40 participants Interventional1998-01-31Completed
Pharmacokinetics of a Medium Chain Triglyceride Oil Oxandrolone Solution vs. Tablets in Healthy Adults: A Relative Bioavailability Study [NCT03218631]Phase 16 participants (Actual)Interventional2017-07-10Completed
A Phase III Randomized Study Comparing The Effects Of Oxandrolone (Oxandrin) And Megestrol Acetate (Megace) On Lean Body Mass, Weight, Body Fat, And Quality Of Life In Patients With Solid Tumors And Weight Loss Receiving Chemotherapy [NCT00070148]Phase 3155 participants (Actual)Interventional2004-03-01Completed
Clinical Trials of Albuterol and Oxandrolone in FSH Dystrophy [NCT00027391]160 participants Interventional2001-09-30Completed
The Relative Effects of Androgen, Estrogen, and the Combination of Androgen and Estrogen on Growth Rate, GH Binding Protein, IGF-I, and Cognitive Function in Growth Hormone-Treated Girls With Turner Syndrome [NCT00001343]Phase 280 participants Interventional1992-12-11Completed
Ability of Oral Steroid (Oxandrolone) to Halt Fatty Infiltration and Aid Rotator Cuff Healing: A Double-Blind, Randomized Clinical Trial [NCT03091075]116 participants (Anticipated)Interventional2018-09-23Active, not recruiting
Placebo Versus Oxandrolone Supplementation in Trauma: A Randomized Multi-Center Double Blind Clinical Trial in High-Energy Lower Extremity Trauma (POST-Injury Trial) [NCT05516849]Phase 30 participants (Actual)Interventional2022-05-19Withdrawn(stopped due to FDA requested manufacturers of Oxandrolone Tablets, to voluntarily remove previously approved drug applications for Oxandrolone from the U.S. market & the funding decided to prematurely terminate the funding.)
Phase II Randomized Study of Oxandrolone vs Placebo for Growth Hormone-Treated Girls With Turner's Syndrome [NCT00004275]Phase 280 participants Interventional1999-10-31Completed
Androgen Effect on Motor/Cognitive Outcome in Klinefelter Syndrome [NCT00348946]Phase 293 participants (Actual)Interventional2006-07-31Completed
CSP #535 - Anabolic Steroid Therapy on Pressure Ulcer Healing in Persons With Spinal Cord Injury [NCT00101361]Phase 3212 participants (Actual)Interventional2005-08-31Terminated(stopped due to futility analysis showed low probability of detecting a significant difference)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00101361 (1) [back to overview]A Healed Pressure Ulcer
NCT00348946 (5) [back to overview]Psychosocial and Behavior Domain
NCT00348946 (5) [back to overview]Cognitive Function and Language
NCT00348946 (5) [back to overview]Motor Function/Strength
NCT00348946 (5) [back to overview]Psychosocial and Behavior Domain
NCT00348946 (5) [back to overview]Working Memory/Attention

A Healed Pressure Ulcer

Patients remained in treatment until full healing of the target pressure ulcer (defined as re-epithelialization to a cicatrix with a dry surface and zero open area for a minimum of 96 hours) or 24 weeks, whichever occured first. (NCT00101361)
Timeframe: healing was measured from randomization to full healing or 24 weeks, whichever occured first.

Interventionparticipants (Number)
1 Oxandrolone26
2 Placebo31

[back to top]

Psychosocial and Behavior Domain

Outcome measures were tested using The Piers-Harris Self Concept Scale. Scoring provides a total standard score and scores on six subscales: physical appearance and attributes, freedom from anxiety, intellectual and school status, behavioral adjustment, happiness and satisfaction, and popularity. Subscales are summed and standardized to provide the total standard score with a mean of 100 and SD of 15. The minimum standard score is 50; the maximum standard score is 145. Higher scores imply better function. (NCT00348946)
Timeframe: 2 years per subject

Interventionunits on a scale (Mean)
Oxandrolone105
Placebo100

[back to top]

Cognitive Function and Language

Outcome measures were tested using the Differential Ability Scales - 2nd edition (DAS-II). DAS-II provides an age- and sex-standardized assessment of intellectual functioning (General Concept Ability subscale similar to IQ) in children ages 2-17 years of age (mean=100, SD=15). The Verbal Cluster measures the child's ability to define words and perform verbal reasoning tasks. The Nonverbal Cluster measures the child's inductive and sequential reasoning abilities. The Spatial Cluster measures visuospatial construction ability, spatial memory, and spatial reasoning. Data is expressed as standard scores with mean of 100 and SD of 15. The minimum standard score is 50; the maximum standard score is 145. Higher scores imply better function. (NCT00348946)
Timeframe: 2 years per subject

,
Interventionscore on a scale (Mean)
DAS: General Concept AbilityDAS: Verbal ClusterDAS: Nonverbal ClusterDAS: Spatial Cluster
Oxandrolone969210296
Placebo949010194

[back to top]

Motor Function/Strength

Outcome measures were tested using the following assessments: Bruininks-Osertesky Test of Motor Proficiency (BOT) subscales of (1) Visual Motor Control, (2) Upper limb Speed, and (3) Strength, Physical and Neurological Evaluation for Soft Signs (PANESS), and Hand Strength Dynamometer. BOT assess the child's motor development and includes standard scores (mean=100, SD=15) and subtest scores and is normed for sex and age (4-14.5 years). PANESS assesses the time required to press thumb to 4 fingers 20 times for the dominant and nondominant hands and includes standard scores (mean=100, SD=15) with age-specific norms (4-18 years). Hand strength dynamometer assess hand strength in the dominant and nondominant hands and includes standard scores (mean=100, SD=15). Data is expressed as standard scores with mean of 100 and SD of 15. The minimum standard score is 50; the maximum standard score is 145. Higher scorers imply better function. (NCT00348946)
Timeframe: 2 years per subject

,
Interventionscore on a scale (Mean)
BOT Visual-motor control SSBOT Upper limb speed SSBOT Strength SSHand Dynamometer SS- dominant handPANESS SS- dominant hand
Oxandrolone86928812391
Placebo81898511891

[back to top]

Psychosocial and Behavior Domain

Outcome measures were tested using the following social assessments: The Child Behavior Checklist (CBCL) and The Children's Depression Inventory (CDI). The CBCL is standardized measure of behavior problems and social competency normed for children ages 4-16. Higher scores indicate more problems, with the cutoff for the clinical range at a t score greater than or equal to 67. The CDI assess cognitive, affective and behavioral signs of depression in children ages 6-17. The CDI total score reflects the presence of overall depressive symptoms. All scores are expressed as t-scores with a mean of 50 and SD of 10. Lower scores imply better function and higher scores indicate more problem behaviors. (NCT00348946)
Timeframe: 2 years per participants

,
Interventionscore on a scale (Mean)
CBCL: behavior total t-scoreCBCL: internalizing total t-scoreCBCL: externalizing total t-scoreCDI: total t-score
Oxandrolone56545145
Placebo59575447

[back to top]

Working Memory/Attention

Outcome measures were tested using the following cognitive assessments: Digit Span Backward, A Neuropsychological Assessment (NEPSY) subscales of (1) Phonemic Fluency and (2) Semantic Fluency, and Connors' Continuous Performance Test (CPT-II) subscales (1) Omissions, (2) Commissions, (3) Hit Reaction, (4) Variability, and (5) Preservations. Digit Span Backward tests working memory and is normed for children ages 5-16 years. Phonemic Fluency measures the number of words that the child can name beginning with the letters F and S (ages 6-12). Semantic Fluency measures the number of words the child can name in the categories food and drink (ages 4-12). CPT-II measures the ability to maintain attention over an extended period of time. All scores are reported as standard scores with a mean of 100 and SD of 15. The minimum standard score is 50; the maximum standard score is 145. Higher scores imply better function. (NCT00348946)
Timeframe: 2 years per participant

,
Interventionscore on a scale (Mean)
Digit span backwardPhonemic fluencySemantic fluencyCPT: omissionsCPT: commissionsCPT: hit reaction timeCPT variabilityCPT: preservations
Oxandrolone96959988101848676
Placebo92919483100808674

[back to top]